On 28 June 2024, the US Food and Drug Administration (FDA) approved a third ustekinumab biosimilar, Pyzchiva (ustekinumab-ttwe). This product has been developed by Samsung Bioepis and is commercialised by Sandoz. It is a biosimilar of reference product Johnson & Johnson’s (J&J) Stelera.
Ustekinumab is a humanized monoclonal antibody that interferes with the triggering of the body’s inflammatory response through the suppression of certain cytokines; it is a human interleukin (IL)–12 and IL-23 antagonist [1].
FDA has approved biosimilar Pyzchiva (ustekinumab-ttwe) in the following formulations: 45 mg/0.5 mL and 90 mg/mL pre-filled syringes for subcutaneous injection, and 130 mg/26 mL (5 mg/mL) single-dose vial for intravenous infusion. Pyzchiva is approved for all indications of its reference medicine, including Crohn's disease, plaque psoriasis, psoriatic arthritis, and ulcerative colitis.
Additionally, FDA granted provisional determination for interchangeability designation for Pyzchiva, as it is currently subject to an unexpired period of exclusivity for the first interchangeable biosimilar, Amgen’s Wezlana (ustekinumab-auub) [2].
The FDA’s approval of Pyzchiva is based on a totality of evidence including analytical, non-clinical and clinical data demonstrating biosimilarity to Stelara, with no clinically meaningful differences in terms of safety, purity and potency. The randomized, double-blind, three-arm, parallel-group, single-dose phase I clinical study (NCT04772274) demonstrated pharmacokinetic (PK) equivalence and comparable safety, tolerability, immunogenicity profiles between Pyzchiva and the reference, Stelara in healthy volunteers. The randomized, double-blind, multicentre phase III clinical study (NCT04967508), conducted in patients with moderate to severe plaque psoriasis, demonstrated biosimilarity of Pyzchiva with the reference through equivalent efficacy and comparable safety and PK profiles up to Week 28. In addition, the phase III study demonstrated biosimilarity of SB17 to Stelara up to Week 28 in terms of efficacy, safety, PK, and immunogenicity.
Sandoz holds the rights to commercialize Pyzchiva in the US, Canada, the European Economic Area (EEA), Switzerland, and the UK. Meanwhile, Samsung Bioepis is responsible for its development, registration, intellectual property, manufacturing, and supply.
Pyzchiva already received EC approval on 22 April 2024 [3]. The product should become available in the US after February 2025, in accordance with the settlement and license agreements made between J&J/Janssen Biotech [4].
The other two ustekinumab biosimilars approved are:
- Alvotech’s Selarsdi (ustekinumab-aekn), approved on 16 Apr 2024 [5] and
- Amgen’s Wezlana (ustekinumab-auub), approved as the first interchangeable ustekinumab on 31 Oct 2023 [6].
Related articles
EMA recommends approval of biosimilar tocilizumab Tofidence and ustekinumab Wezenla
Amgen announces positive phase III results for ustekinumab biosimilar
Phase I trials started for aflibercept and ustekinumab biosimilars
|
LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View the latest headline article: La FDA aprueba el primer biosimilar de eculizumab, Bkemv, para dos enfermedades raras Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Ver el último artículo de cabecera: La FDA aprueba el primer biosimilar de eculizumab, Bkemv, para dos enfermedades raras !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of ustekinumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 16]. Available from: www.gabionline.net/biosimilars/general/biosimilars-of-ustekinumab
2. GaBI Online - Generics and Biosimilars Initiative. FDA approves first interchangeable ustekinumab biosimilar Wezlana [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 16]. Available from: www.gabionline.net/biosimilars/news/fda-approves-first-interchangeable-ustekinumab-biosimilar-wezlana
3. GaBI Online - Generics and Biosimilars Initiative. EC biosimilar approvals: Omlyclo, Jubbonti/Wyost, and Pyzchiva [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 16]. Available from: www.gabionline.net/biosimilars/news/ec-biosimilar-approvals-omlyclo-jubbonti-wyost-and-pyzchiva
4. GaBI Online - Generics and Biosimilars Initiative. J&J lawsuits settled over ustekinumab biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 16]. Available from: www.gabionline.net/pharma-news/j-j-lawsuits-settled-over-ustekinumab-biosimilars
5. GaBI Online - Generics and Biosimilars Initiative. FDA approves ustekinumab, trastuzumab, and tocilizumab biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 16]. Available from: www.gabionline.net/biosimilars/news/fda-approves-ustekinumab-trastuzumab-and-tocilizumab-biosimilars
6. GaBI Online - Generics and Biosimilars Initiative. FDA approves first interchangeable ustekinumab biosimilar Wezlana [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 16]. Available from: www.gabionline.net/biosimilars/news/fda-approves-first-interchangeable-ustekinumab-biosimilar-wezlana
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment